![]() ![]() Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. ![]() While Gilead and Regeneron are Zacks Rank #1 (Strong Buy) stocks, Amgen is a Zacks Rank #2 (Buy) stock. Some better-ranked stocks in the biotech sector include Gilead Sciences Inc. Kite Pharma is a Zacks Rank #3 (Hold) stock. If all goes well, KTE-C19 could be launched as early as 2017. With KTE-C19 being Kite Pharma’s lead pipeline candidate, investor focus will remain on any updates on this candidate. Kite Pharma is one of the major players looking to bring immuno-oncology treatments to market. The European Commission has approved Gilead Science Inc (NASDAQ: GILD) company Kite Pharmas CAR T-cell therapy Tecartus (brexucabtagene autoleucel) for patients 26 years and above with relapsed. The single arm, open-label, multi-center study is being conducted to evaluate KTE-C19’s safety and efficacy in patients with refractory diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL). The company said that it remains on track to move on to the second part of the study with data expected in 2016. Kite Pharma intends to present top-line data from the phase I part of the study at the annual meeting of the American Society of Hematology (ASH) in December. These patients are being monitored to determine durability of treatment. ![]() The company said that multiple patients have been treated with complete responses being observed by investigators shortly after treatment was administered. Moreover, following discussions with the FDA, the company continued to enroll and treat patients in the study which was never placed on clinical hold. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |